On March 29, the 2021 annual report disclosed by senxuan Pharmaceutical (830946, BJ; the previous closing price was 17.07 yuan), an API enterprise of the Beijing stock exchange, showed that the company’s revenue in 2021 was 564 million yuan, a year-on-year increase of 2.78%, and the net profit attributable to shareholders of listed companies was 131 million yuan, a year-on-year decrease of 9.38%.
Senxuan pharmaceutical has been sought after by the capital market for its ability to produce ritonavir intermediates, and its share price has increased by more than three times since it was listed on the Beijing stock exchange. However, previously, the company denied supplying ritonavir series intermediates to Pfizer.
On the morning of March 30, a staff member of senxuan pharmaceutical Securities Department told the reporter of the daily economic news that the company has not considered transferring to the gem for the time being.
company’s raw materials rose more
Senxuan pharmaceutical was founded in 2003, and the actual controller is Nantong SASAC. In November 2021, it became the first batch of companies listed on the Beijing stock exchange. At present, the company is mainly engaged in the R & D, production and sales of chemical APIs, pharmaceutical intermediates and oxygen-containing heterocyclic chemical intermediates.
According to the annual report data of senxuan pharmaceutical in 2021, the company achieved a revenue of 564 million yuan, a year-on-year increase of 2.78%, and the net profit attributable to the shareholders of the listed company was 131 million yuan, a year-on-year decrease of 9.38%. In terms of products, the revenue of API was 284 million yuan, a year-on-year decrease of 12.24%; The revenue of pharmaceutical intermediates was 84.45 million yuan, a year-on-year increase of 21.30%; The revenue of oxygenated heterocyclic chemical intermediates was 187 million yuan, a year-on-year increase of 26.51%.
Senxuan pharmaceutical said in the previously released performance express that the main reasons for the increase of income but not profit in 2021 are: on the one hand, due to the covid-19 epidemic, the company’s export revenue decreased significantly, but at the same time, due to the influence of the double control and double reduction policy, the company covered the decline of export revenue by strengthening the development of Chinese customers and raising product prices; On the other hand, affected by the above two factors, the prices of chemical raw materials and energy increased, and the international logistics cost increased significantly, resulting in the decline of the company’s overall gross profit.
The reporter of the daily economic news noted that the overall gross profit margin of senxuan medicine in 2021 was 44.87%, lower than 48.36% in 2020, the first decline since 2018. In terms of various businesses, the gross profit margin of pharmaceutical intermediates and oxygen-containing heterocyclic chemical intermediates decreased by more than 10 percentage points. In addition, the company’s revenue in China in 2021 was 452 million yuan, a year-on-year increase of 8.41%, and the foreign revenue was 112 million yuan, a year-on-year decrease of 15.04%.
On the morning of March 30, the staff of senxuan pharmaceutical Securities Department said in an interview with the reporter of daily economic news that the decline in gross profit margin was mainly due to the covid-19 epidemic and the dual control policy. The company’s raw materials increased more and the logistics costs increased more.
company said it had no board transfer plan
Previously, senxuan medicine was regarded as a covid-19 drug concept stock and was highly praised by the market. Since its listing on the Beijing stock exchange, the share price has increased by more than three times. Paxlovid, an oral covid-19 drug developed by Pfizer, mainly consists of ritonavir, while senxuan pharmaceutical’s products happen to include ritonavir intermediate.
However, the company quickly denied supplying ritonavir series intermediates to Pfizer. Sen Xuan pharmaceutical announced earlier that the company did not sign a contract for the purchase and sale of ritonavir medicine intermediates with Pfizer Inc, and did not supply ritonavir series intermediates. The company has sold the ritonavir series intermediates, mainly used in the synthesis of RT anti AIDS drug. Senxuan pharmaceutical said that in 2021, the company’s ritonavir pharmaceutical intermediate is expected to achieve a sales volume of 11 tons and a sales revenue of 16.84 million yuan, with a year-on-year decrease of about 33% and 32% respectively.
In the annual report, Sen Xuan medicine said that Future Ltd will continue to increase R & D investment in the fight against AIDS medicine intermediates, especially the research and development of intermediates of ritonavir and ritonavir.
When the reporter asked about the company’s capacity planning for ritonavir, the staff of senxuan pharmaceutical Securities Department said that it would make appropriate adjustments according to the market situation in the future.
According to the research report released by Soochow Securities Co.Ltd(601555) recently, Hanbo hi tech and taixiang shares were successfully transferred to the gem on March 11 and March 25 respectively, realizing the real interconnection of China’s multi-level capital market. In addition, according to the continuous listing time of Beijing stock exchange for more than one year, the total share capital of no less than 30 million yuan, the number of shareholders of no less than 1000 and the financial requirements of gem / scientific innovation board, Soochow Securities Co.Ltd(601555) it is estimated that 19 companies may be eligible for board transfer, including senxuan medicine.
In this regard, the above staff of senxuan pharmaceutical Securities Department said that the company has not considered transferring to the gem for the time being.
